Drug intelligence / Profile preview

LAU_XT-13

Development stage: Unknown
Lead developer: Vectans Pharma
Modality: Small Molecules
Administration: Buccal

Overview

LAU_XT-13 is an investigational muco-adhesive buccal tablet developed by Vectans Pharma for the treatment of xerostomia (dry mouth). The formulation utilizes Vectans' proprietary Lauriad technology, which enables the drug to adhere to the oral mucosa and provide sustained release of the active ingredient directly into the oral cavity. This approach aims to improve the management of dry mouth symptoms, which are often associated with conditions like Sjögren's syndrome or as a side effect of radiotherapy for head and neck cancer. As of late 2021, the program was in Phase 1 clinical development.

Beyond the preview

Go deeper on LAU_XT-13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAU_XT-13.

Explore the full profile